A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Public ClinicalTrials.gov record NCT05919693. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Study identification
- NCT ID
- NCT05919693
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 33 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2023 (Actual)
- Primary completion
- Aug 26, 2024 (Actual)
- Completion
- Aug 26, 2024 (Actual)
- Last update posted
- Nov 3, 2026
2023 – 2024
United States locations
- U.S. sites
- 27
- U.S. states
- 10
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix, AZ | Phoenix | Arizona | 85032 | — |
| Bakersfield, CA | Bakersfield | California | 93309 | — |
| Modesto, CA | Modesto | California | 95356 | — |
| Mountain View, CA | Mountain View | California | 94040 | — |
| Sacramento, CA | Sacramento | California | 95825 | — |
| Sacramento, CA | Sacramento | California | 95841 | — |
| Colorado Springs, Colorado | Colorado Springs | Colorado | 80909 | — |
| Lakewood, CO | Lakewood | Colorado | 80288 | — |
| Pompano Beach | Pompano Beach | Florida | 33064 | — |
| Lemont, NV | Lemont | Illinois | 60439 | — |
| Hagerstown, MD | Hagerstown | Maryland | 21740 | — |
| Reno, NV | Reno | Nevada | 89502 | — |
| West Columbia, SC | West Columbia | South Carolina | 29169 | — |
| Germantown, TN | Germantown | Tennessee | 38138 | — |
| Knoxville, TN | Knoxville | Tennessee | 37922 | — |
| Nashville, TN | Nashville | Tennessee | 37203 | — |
| Abilene, TX | Abilene | Texas | 79606 | — |
| Amarillo, TX | Amarillo | Texas | 79109 | — |
| Austin, TX | Austin | Texas | 78705 | — |
| Bellaire, TX | Bellaire | Texas | 77401 | — |
| Dallas, TX | Dallas | Texas | 75231 | — |
| Katy, TX | Katy | Texas | 77494 | — |
| McAllen, TX | McAllen | Texas | 78503 | — |
| Plano, TX | Plano | Texas | 75075 | — |
| Round Rock, TX | Round Rock | Texas | 78681 | — |
| San Antonio, TX | San Antonio | Texas | 78240 | — |
| The Woodlands, TX | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05919693, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2026 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05919693 live on ClinicalTrials.gov.